Literature DB >> 15510176

Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.

P Henning1, K M E Andersson, K Frykholm, A Ali, M K Magnusson, P-A Nygren, O Granio, S S Hong, P Boulanger, L Lindholm.   

Abstract

Most human carcinoma cell lines lack the high-affinity receptors for adenovirus serotype 5 (Ad5) at their surface and are nonpermissive to Ad5. We therefore tested the efficiency of retargeting Ad5 to alternative cellular receptors via immunoglobulin (Ig)-binding domains inserted at the extremity of short-shafted, knobless fibers. The two recombinant Ad5's constructed, Ad5/R7-Z(wt)-Z(wt) and Ad5/R7-C2-C2, carried tandem Ig-binding domains from Staphylococcal protein A (abbreviated Z(wt)) and from Streptococcal protein G (C2), respectively. Both viruses bound their specific Ig isotypes with the expected affinity. They transduced human carcinoma cells independently of the CAR pathway, via cell surface receptors targeted by specific monoclonal antibodies, that is, EGF-R on A549, HT29 and SW1116, HER-2/neu on SK-OV-3 and SK-BR-3, CA242 (epitope recognized by the monoclonal antibody C242) antigen on HT29 and SW1116, and PSMA (prostate-specific membrane antigen) expressed on HEK-293 cells, respectively. However, Colo201 and Colo205 cells were neither transduced by targeting CA242 or EGF-R nor were LNCaP cells transduced by targeting PSMA. Our results suggested that one given surface receptor could mediate transduction of certain cells but not others, indicating that factors and steps other than cell surface expression and virus-receptor interaction are additional determinants of Ad5-mediated transduction of tumor cells. Using penton base RGD mutants, we found that one of these limiting steps was virus endocytosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15510176     DOI: 10.1038/sj.gt.3302408

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  17 in total

1.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 3.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

4.  The effect of fiber truncations on the stability of adenovirus type 5.

Authors:  Grit Kupgan; Danielle C Hentges; Nathan J Muschinske; William D Picking; Wendy L Picking; Joshua D Ramsey
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

Review 5.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

6.  Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery.

Authors:  Jiali Li; Sonya Lad; Guang Yang; Yunping Luo; Milena Iacobelli-Martinez; F James Primus; Ralph A Reisfeld; Erguang Li
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

7.  Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).

Authors:  Adriana S Beltran; Pilar Blancafort
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

8.  Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.

Authors:  Mohan Babu Appaiahgari; Ravindra Mohan Pandey; Sudhanshu Vrati
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

9.  A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Authors:  M K Magnusson; R Kraaij; R M Leadley; C M A De Ridder; W M van Weerden; K A J Van Schie; M Van der Kroeg; R C Hoeben; N J Maitland; L Lindholm
Journal:  Hum Gene Ther       Date:  2011-10-12       Impact factor: 5.695

10.  Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.

Authors:  Stéphanie Corjon; Gaëlle Gonzalez; Petra Henning; Alexei Grichine; Leif Lindholm; Pierre Boulanger; Pascal Fender; Saw-See Hong
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.